ASML’s current share buyback program was announced on 10 November 2022, and details are available on our website at https://www.asml.com/en/news/share-buybacks This ...

In their commentary, BofA Securities analysts stated, "We maintain our Buy rating with an unchanged PO of €803." This reiteration comes after ASML's strong quarterly performance and the positive ...

The latest trading session saw ASML (ASML) ending at $743.09, denoting a -0.23% adjustment from its last day's close. This change was narrower than the S&P 500's 0.43% loss on the day. Meanwhile ...

While ASML’s leadership in semiconductor manufacturing equipment remains unchallenged, near-term risks such as export restrictions and premium valuation suggest that holding the stock is the bes ...

One of the stocks that is poised to win over the long term from the AI boom is ASML (NASDAQ: ASML), the leading maker of lithography equipment used to make semiconductors. Let's take a look at ...

But over the past 12 months, ASML's stock declined 25% as the Nasdaq Composite rallied nearly 20%. That pullback, which was largely driven by macro and regulatory concerns, could represent a great ...

SAN JOSE, California, Feb 24 (Reuters) - (This Feb. 24 story has been corrected to say that Intel is using 18A manufacturing technology to test the high NA tools, not using high NA machines to ...

VELDHOVEN, the Netherlands, March 5, 2025 – Today, ASML Holding NV (ASML) has published its 2024 Annual Reports. The 2024 Annual Reports ('Powering technology forward with you') highlight ASML ...

I foresee a small but significant risk that ASML may lose its DUV export license to China, which would severely impact the expected revenue normalization in this region during 2025. A downward ...

AMSTERDAM (Reuters) -ASML, the computer chip equipment maker that has been hit by successive waves of U.S.-led restrictions on exports to China, said in its annual report on Wednesday that ...

Restrictions on exports to China have also weighed on the sector. As a result, ASML stock is now down 32% from its peak last July, but for patient investors, that sell-off sets up a buying ...